Association of changes in expression of HDAC and SIRT genes after drug treatment with cancer cell line sensitivity to kinase inhibitors

Julia Krushkal,Yingdong Zhao,Kyle Roney,Weimin Zhu,Alan Brooks,Deborah Wilsker,Ralph E Parchment,Lisa M McShane,James H Doroshow,Julia KrushkalYingdong ZhaoKyle RoneyWeimin ZhuAlan BrooksDeborah WilskerRalph E. ParchmentLisa M. McShaneJames H. Doroshowa Biometric Research Program,Division of Cancer Treatment and Diagnosis,National Cancer Institute,Rockville,MD,USAb Department of Biostatistics and Bioinformatics,George Washington University,Washington,DC,USAc Clinical Pharmacodynamic Biomarkers Program,Applied/Developmental Research Directorate,Frederick National Laboratory for Cancer Research,Frederick,MD,USAd Division of Cancer Treatment and Diagnosis and Center for Cancer Research,National Cancer Institute,Bethesda,MD,USA

DOI: https://doi.org/10.1080/15592294.2024.2309824

2024-02-19

Epigenetics

Abstract:Histone deacetylases (HDACs) and sirtuins (SIRTs) are important epigenetic regulators of cancer pathways. There is a limited understanding of how transcriptional regulation of their genes is affected by chemotherapeutic agents, and how such transcriptional changes affect tumour sensitivity to drug treatment. We investigated the concerted transcriptional response of HDAC and SIRT genes to 15 approved antitumor agents in the NCI-60 cancer cell line panel. Antitumor agents with diverse mechanisms of action induced upregulation or downregulation of multiple HDAC and SIRT genes. HDAC5 was upregulated by dasatinib and erlotinib in the majority of the cell lines. Tumour cell line sensitivity to kinase inhibitors was associated with upregulation of HDAC5, HDAC1 , and several SIRT genes. We confirmed changes in HDAC and SIRT expression in independent datasets. We also experimentally validated the upregulation of HDAC5 mRNA and protein expression by dasatinib in the highly sensitive IGROV1 cell line. HDAC5 was not upregulated in the UACC-257 cell line resistant to dasatinib. The effects of cancer drug treatment on expression of HDAC and SIRT genes may influence chemosensitivity and may need to be considered during chemotherapy.

genetics & heredity,biochemistry & molecular biology

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is: to explore the effects of 15 approved anti - tumor drugs on the gene expression of HDAC (histone deacetylase) and SIRT (sirtuin) in cancer cell lines, and to analyze the association between these gene expression changes and the sensitivity of cancer cell lines to kinase inhibitors. Specifically, the researchers focused on: - **The influence of chemotherapeutic drugs on the gene expression of HDAC and SIRT**: To understand how different anti - cancer drugs change the expression levels of these genes. - **The relationship between gene expression changes and drug sensitivity**: To evaluate whether the changes in the gene expression of HDAC and SIRT affect the sensitivity of cancer cells to specific drugs, especially kinase inhibitors. ### Research background HDACs and SIRTs are important epigenetic regulators and play a crucial role in the occurrence and development of cancer. However, at present, little is known about how chemotherapeutic drugs affect the transcriptional regulation of these genes and their impact on the drug sensitivity of tumor cells. Therefore, understanding the expression changes of these genes after drug treatment is helpful to reveal potential treatment targets and mechanisms. ### Research methods The researchers used the data of the NCI - 60 cancer cell line panel. By analyzing the expression changes of HDAC and SIRT genes before and after the treatment with 15 FDA - approved anti - tumor drugs, they identified consistent transcriptional changes. At the same time, they also examined the association between the basal expression levels of these genes and drug responses. ### Key findings - **Up - regulation of HDAC5**: The study found that dasatinib and erlotinib significantly up - regulated the expression of HDAC5 in most cell lines. - **Association with drug sensitivity**: The sensitivity of tumor cell lines to kinase inhibitors is related to the up - regulation of HDAC5, HDAC1 and multiple SIRT genes. - **Experimental verification**: Through independent data sets and experimental verification, it was confirmed that the up - regulation of HDAC5 mRNA and protein expression in the highly sensitive IGROV1 cell line, while no up - regulation was observed in the UACC - 257 cell line which is resistant to dasatinib. In conclusion, this study reveals that the changes in the gene expression of HDAC and SIRT may affect the sensitivity to chemotherapeutic drugs, providing a new perspective and potential treatment strategies for future cancer treatment.

Association of changes in expression of HDAC and SIRT genes after drug treatment with cancer cell line sensitivity to kinase inhibitors

Sirtuin 1 facilitates chemoresistance of pancreatic cancer cells by regulating adaptive response to chemotherapy-induced stress.

Pharmaco-transcriptomic correlation analysis reveals novel responsive signatures to HDAC inhibitors and identifies Dasatinib as a synergistic interactor in small-cell lung cancer

Recent Advances of SIRT1 and Implications in Chemotherapeutics Resistance in Cancer.

Immune modulation underpins the anti-cancer activity of HDAC inhibitors

Proteomics analysis of histone deacetylase inhibitor-resistant solid tumors reveals resistant signatures and potential drug combinations

Histone deacetylase (HDAC) encoding gene expression in pancreatic cancer cell lines and cell sensitivity to HDAC inhibitors

Altered histone acetylation patterns in pancreatic cancer cell lines induce subtype‐specific transcriptomic and phenotypical changes

Hyper-acetylation contributes to the sensitivity of chemo-resistant prostate cancer cells to histone deacetylase inhibitor Trichostatin A

HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma

Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer

Histone Deacetylase Inhibitors Directly Modulate T Cell Gene Expression and Signaling and Promote Development of Effector-Exhausted T Cells in Murine Tumors

Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials.

Systematic identification of genomic markers of drug sensitivity in cancer cells

Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi

Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer

Drug screening approach combines epigenetic sensitization with immunochemotherapy in cancer

Silencing HDAC1 Expression Regulates Extracellular Regulated Protein Kinases/Mitogen-Activated Protein Kinase Signaling Activation and Enhances Chemosensitivity of Ovarian Carcinoma

Single-cell transcriptional changes associated with drug tolerance and response to combination therapies in cancer

ATF3 Repression of BCL-XL Determines Apoptotic Sensitivity to HDAC Inhibitors across Tumor Types

Abstract 4582: HDAC6 inhibition reshapes the epigenome of cancer via P300 stabilization